Clinical Trial Update: Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study of HepaStem for urea cycle disorders and Crigler-Najjar syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crigler-najjar Syndrome
• Urea Cycle Disorders

Drugs mentioned

• HepaStem

Snippet

Sponsor: Cellaion SA | Conditions: Urea Cycle Disorders, Crigler Najjar Syndrome | Phase 1, Phase 2 | Status: COMPLETED